Navigation Links
Phlo Affiliate Begins Roll Out to Metropolitan New York City Account Base
Date:12/27/2007

JACKSONVILLE, Fla., Dec. 27 /PRNewswire-FirstCall/ -- Phlo Corporation (Pink Sheets: PHLC) ("Phlo") announced today that one of its affiliates (the "Company") has completed the initial shipment of its vitality beverage product, AQISS(TM), as part of a roll out of the product in the metropolitan New York City area, including Manhattan, Brooklyn, Queens, the Bronx, and Long Island.

AQISS(TM) is being launched in a key account base, some of which are as follows:

-- Financial institutions, including Goldman Sachs, Morgan Stanley,

Merrill Lynch, the New York Stock Exchange cafeteria, HSBC, and UBS.

-- Supermarkets and prepared food markets, including Food Emporium

supermarkets, D'Agostino's supermarkets, Fairway Markets, Balducci's,

Dean & Deluca, Associated Supermarkets, Pax Wholesome Foods, Ernest

Klein, Apple Tree Supermarket, and Amish Markets, among others.

-- Numerous restaurants and cafes, including Europa Cafes, Cafe Duke,

Eli's Manhattan, Elis' Vinegar Factory, Cafe Metro, Zeytuna, and

Garden of Eden.

AQISS(TM) features the Company's Instant Nano Hydration and Cell Armor technologies, providing instant, direct delivery of rehydration and cell-repair-and-protection payloads into the bloodstream beginning through the membranes of the mouth. These Instant Nano Hydration and Cell Armor technologies help provide sustained wellness necessary for life's performances and vigorous longevity. In addition, the Company's nano-encapsulation technology prevents the destruction of its active payloads in the stomach.

Phlo is a biotechnology company and a manufacturer and marketer of products (primarily liquids) containing patented and patent-pending biotechnologies. Phlo is focusing its technology generation and acquisition efforts on those technologies related to enhancing cognition and personal performance, reducing the effects of aging, and preventing or ameliorating cancer.

Certain statements made herein that are not historical constitute "forward-looking" statements within the meaning of the Private Litigation Reform Act of 1995 and may contain words such as "anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify such forward-looking statements. Such statements are based on a number of assumptions and on information and estimates supplied to Phlo Corporation by sources currently available to it. Such assumptions and estimates are subject to uncertainties, contingencies, and other factors, many of which are beyond Phlo Corporation's control. Actual results may differ materially from the statements set forth above.


'/>"/>
SOURCE Phlo Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Phlo Affiliate Reports Expanded Coverage to Oregon Border
2. Phlo Affiliate Reports AQUISS to be Sold in 450 7-Eleven Stores
3. Phlo Affiliate Hires Chief Marketing Officer With Extensive Global Experience
4. Phlo Affiliate to Launch AQUISS(TM) on East Coast
5. Phlo Affiliate Names Director Of Marketing
6. Phlo Affiliate Ships Product to Launch 450 7-Eleven Stores
7. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
8. Genzyme Begins Major Expansion of Boston Manufacturing Facility
9. Medical Services Begins Working With United States Companies for Distribution of Its Products
10. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
11. Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):